Skip to main content
. 2023 Mar 3;14:1041042. doi: 10.3389/fgene.2023.1041042

TABLE 3.

Associations between GSTK1 expression and the clinicopathological features of HNSC.

Characteristic Low expression of GSTK1 High expression of GSTK1 p-value
n 251 251
T stage, n (%) 0.082
T1 13 (2.7%) 20 (4.1%)
T2 63 (12.9%) 81 (16.6%)
T3 66 (13.6%) 65 (13.3%)
T4 101 (20.7%) 78 (16%)
N stage, n (%) 0.198
N0 124 (25.8%) 115 (24%)
N1 43 (9%) 37 (7.7%)
N2 67 (14%) 87 (18.1%)
N3 5 (1%) 2 (0.4%)
M stage, n (%) 0.214
M0 239 (50.1%) 233 (48.8%)
M1 1 (0.2%) 4 (0.8%)
Clinical stage, n (%) 0.897
Stage I 10 (2%) 9 (1.8%)
Stage II 45 (9.2%) 50 (10.2%)
Stage III 49 (10%) 53 (10.9%)
Stage IV 139 (28.5%) 133 (27.3%)
Lymph node dissection, n (%) 0.403
No 41 (8.2%) 49 (9.8%)
Yes 209 (41.9%) 200 (40.1%)
Smoker, n (%) 0.035
No 45 (9.1%) 66 (13.4%)
Yes 200 (40.7%) 181 (36.8%)
Alcohol history, n (%) 0.046
No 68 (13.8%) 90 (18.3%)
Yes 177 (36%) 156 (31.8%)
Gender, n (%) 0.267
Female 61 (12.2%) 73 (14.5%)
Male 190 (37.8%) 178 (35.5%)
Age, median (SD) 60.11 (11.66) 62.05 (12.08) 0.068